← Back to Search

Cyclin Dependent Kinase Inhibitor

CYC065 for Cancer

Phase 1

Waitlist Available

Led By Geoffrey Shapiro, MD

Research Sponsored by Cyclacel Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up cycle 1(each cycle is 21 -28 days)

Awards & highlights

Study Summary

This trial is testing a new cancer treatment by giving increasing doses to patients to see what works best.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ cycle 1(each cycle is 21 -28 days)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~cycle 1(each cycle is 21 -28 days)

This trial's timeline: 3 weeks for screening, Varies for treatment, and cycle 1(each cycle is 21 -28 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of patients who experience dose-limiting toxicities

Secondary outcome measures

Half-life of CYC065

Plasma concentrations

changes in certain protein levels in peripheral white blood cells by western blots

Trial Design

3Treatment groups

Experimental Treatment

Group I: CYC065 - Oral (Part 3 - ongoing)Experimental Treatment1 Intervention

CYC065 will be administered orally on Days 1, 2, 8 and 9 every 3 weeks

Group II: CYC065 - 4 hour infusion (Part 1 completed)Experimental Treatment1 Intervention

CYC065 will be administered by 4 -hour infusion every 3 weeks.

Group III: CYC065 - 1 hour infusion (Part 2 - ongoing)Experimental Treatment1 Intervention

CYC065 will be administered by 1 - hour infusion on Days 1, 2, 8, and 9 every 3 weeks

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CYC065

2019

Completed Phase 1

~80

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Cyclacel Pharmaceuticals, Inc.Lead Sponsor

19 Previous Clinical Trials

2,419 Total Patients Enrolled

Geoffrey Shapiro, MDPrincipal InvestigatorDana-Farber Cancer Institute

3 Previous Clinical Trials

177 Total Patients Enrolled

Media Library

CYC065 (Cyclin Dependent Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02552953 — Phase 1

Cancer Research Study Groups: CYC065 - Oral (Part 3 - ongoing), CYC065 - 4 hour infusion (Part 1 completed), CYC065 - 1 hour infusion (Part 2 - ongoing)

Cancer Clinical Trial 2023: CYC065 Highlights & Side Effects. Trial Name: NCT02552953 — Phase 1

CYC065 (Cyclin Dependent Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02552953 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What adverse effects can be associated with CYC065 consumption?

"With limited data indicating the efficacy and safety of CYC065, our team at Power rated this drug a 1 on its scale."

Answered by AI

Are there any documented precedents of research involving CYC065?

"Presently, 5 clinical trials are running for CYC065. None of these extant studies have reached Phase 3 yet. While the majority of tests take place in Duarte, California, 11 sites across the country are conducting research into this medication."

Answered by AI

Does this research initiative open up any new avenues of exploration?

"CYC065 has been researched since 2015, when it was first sponsored by Cyclacel Pharmaceuticals, Inc. After the successful Phase 1 trial of 70 patients in that year, 5 live studies are now being conducted across 3 nations and 5 cities."

Answered by AI

Is this research endeavor actively seeking out participants?

"Sadly, this medical trial is no longer actively looking for patients. It was first posted on September 1st 2015 and updated most recently in April 22nd 2022. However, 486 other clinical trials are recruiting participants to study malignancies and 5 studies related to CYC065 are still accepting enrollees."

Answered by AI

To what extent can participants be accepted into this trial?

"Unfortunately, this experiment is not currently enrolling. It was first listed on September 1st 2015 and the latest update occured April 22nd 2022. If you are looking for alternative trials, 486 studies concerning cancers are seeking participants while 5 separate CYC065 clinicals require additional volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

2015. "A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02552953.